Enterprise Value

-50.19M

Cash

192.9M

Avg Qtr Burn

-31.81M

Short % of Float

7.83%

Insider Ownership

2.20%

Institutional Own.

-

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ANX005 (IV) Details
Huntington's disease, Brain disease

Phase 3

Initiation

ANX005 (IV) Details
Guillian-Barre syndrome, Autoimmune disease

Phase 2/3

Data readout

ANX007 (IVT) Details
Geographic atrophy

Phase 2

Data readout

ANX005 (IV) Details
Amyotrophic lateral sclerosis, Neurodegenerative disease

Phase 2a

Data readout

ANX009 Details
Lupus nephritis

Phase 1b

Data readout

ANX105 Details
Autoimmune disease, Neurodegenerative disease

Phase 1

Data readout

ANX1502 Details
Autoimmune disease

Phase 1a

Data readout

ANX005 (IV) Details
Warm autoimmune hemolytic anemia, Autoimmune disease

Failed

Discontinued